D:\Program Files\sunseb\Queries\3





chain nodes:
7 9 11 43 60 61 62 63 67
ring nodes:
1 2 3 4 5 6 12 13 14 15 16 17 18 19 20 21
22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
37 44 45 46 47 48 49 50 51 52 53 54 55 56 57
58 59
chain bonds:
7-9 9-11 9-43 60-61 62-63
ring bonds:
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15
15-16 16-17 18-19 18-23 19-20 20-21 21-22 22-23
22-24 23-27 24-25 25-26 26-27 28-29 28-33 29-30
30-31 31-32 32-33 32-34 33-37 34-35 35-36 36-37
44-45 44-49 45-46 46-47 47-48 48-49 50-51 50-55
51-52 52-53 53-54 54-55 54-56 55-59 56-57 57-58
58-59
exact/norm bonds:
1-2 1-6 2-3 3-4 4-5 5-6 7-9 9-11 9-43
exact bonds:
60-61 62-63
normalized bonds:
12-13 12-17 13-14 14-15 15-16 16-17 18-19 18-23
19-20 20-21 21-22 22-23 22-24 23-27 24-25 25-26
26-27 28-29 28-33 29-30 30-31 31-32 32-33 32-34
33-37 34-35 35-36 36-37 44-45 44-49 45-46 46-47
47-48 48-49 50-51 50-55 51-52 52-53 53-54 54-55
54-56 55-59 56-57 57-58 58-59
isolated ring systems:
containing 1 : 12 : 18 : 28 : 44 : 50 :



```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1            Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2            "Ask CAS" for self-help around the clock
 NEWS  3   FEB 25   CA/CAPLUS - Russian Agency for Patents and Trademarks
                    (ROSPATENT) added to list of core patent offices covered
 NEWS  4   FEB 28   PATDPAFULL - New display fields provide for legal status
                    data from INPADOC
 NEWS  5   FEB 28   BABS - Current-awareness alerts (SDIs) available
 NEWS  6   FEB 28   MEDLINE/LMEDLINE reloaded
 NEWS  7   MAR 02   GBFULL: New full-text patent database on STN
 NEWS  8   MAR 03   REGISTRY/ZREGISTRY - Sequence annotations enhanced
 NEWS  9   MAR 03   MEDLINE file segment of TOXCENTER reloaded
 NEWS  10  MAR 22   KOREAPAT now updated monthly; patent information enhanced
 NEWS  11  MAR 22   Original IDE display format returns to REGISTRY/ZREGISTRY
 NEWS  12  MAR 22   PATDPASPC - New patent database available
 NEWS  13  MAR 22   REGISTRY/ZREGISTRY enhanced with experimental property tags
 NEWS  14  APR 04   EPFULL enhanced with additional patent information and new
                    fields
 NEWS  15  APR 04   EMBASE - Database reloaded and enhanced
 NEWS  16  APR 18   New CAS Information Use Policies available online
 NEWS  17  APR 25   Patent searching, including current-awareness alerts (SDIs),
                    based on application date in CA/CAplus and USPATFULL/USPAT2
                    may be affected by a change in filing date for U.S.
                    applications.
 NEWS  18  APR 28   Improved searching of U.S. Patent Classifications for
                    U.S. patent records in CA/CAplus

 NEWS EXPRESS  JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:51:14 ON 03 MAY 2005

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 16:51:22 ON 03 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)
```

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 MAY 2005 HIGHEST RN 849658-68-0
DICTIONARY FILE UPDATES: 2 MAY 2005 HIGHEST RN 849658-68-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

=> s l1
SAMPLE SEARCH INITIATED 16:58:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 148 TO ITERATE

100.0% PROCESSED 148 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2231 TO 3689
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 160.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 16:58:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2750 TO ITERATE

100.0% PROCESSED 2750 ITERATIONS 29 ANSWERS
SEARCH TIME: 00.00.01

```
L3            29 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   166.06     166.27

FILE 'HCAPLUS' ENTERED AT 16:58:17 ON 03 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 3 May 2005  VOL 142 ISS 19
FILE LAST UPDATED: 2 May 2005  (20050502/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l3
L4             9 L3

=> s l4 and zhonghui, l?/au
               0 ZHONGHUI, L?/AU
L5             0 L4 AND ZHONGHUI, L?/AU

=> s l4 and maduskuie, t?/au
              34 MADUSKUIE, T?/AU
L6             3 L4 AND MADUSKUIE, T?/AU

=> d l6, ibib abs hitstr, 1-3

L6   ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2005 ACS on STN
```

Full Text | Citing References

```
ACCESSION NUMBER:          2004:310829  HCAPLUS
DOCUMENT NUMBER:           140:303552
TITLE:                     Preparation of β-amino acid derivatives as
                           inhibitors of matrix metalloproteases and TNF-α
INVENTOR(S):               Duan, Jingwu; King, Bryan W.; Decicco, Carl;
                           Maduskuie, Thomas P.; Voss, Mathew E.
PATENT ASSIGNEE(S):        USA
SOURCE:                    U.S. Pat. Appl. Publ., 150 pp.
                           CODEN: USXXCO
DOCUMENT TYPE:             Patent
LANGUAGE:                  English
FAMILY ACC. NUM. COUNT:    1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004072802	A1	20040415	US 2002-267207	20021009
PRIORITY APPLN. INFO.:			US 2002-267207	20021009
OTHER SOURCE(S):	MARPAT 140:303552			

AB Novel β-amino acid derivs. A-CR3R4aCR2R4NR1CO-X-Z-Ua-Xa-Ya-Za [A = CO2H, SH, CH2SH, S(O)Ra:NH (Ra = H, alkyl), P(O)(OH)2, etc.; X, Xa is absent or alkylene, alkenylene or alkynylene; Z is absent or substituted C3-13 carbocycle or 5-14 membered heterocycle; Ua is absent or O, NRa1 [Ra1 = H, (un)substituted alkyl, alkenyl or alkynyl; Ra and Ra1 may form a ring], CO, CO2, O2C, CONRa1, S(O)p (p = 0-2), etc.; Ya is absent or O, NRa1, S(O)p or CO; Za is H, substituted C3-13 carbocycle or 5-14 membered heterocycle; R1 is H, alkyl, Ph, benzyl; R2 is Q (Q is H, substituted carbocycle or heterocycle), alkylene-Q, (CRaRa1)r1O(CRaRa1)r-Q (r, r1 = 0-4), (CRaRa1)r1NRa(CRaRa1)r-Q, etc.; R3 = Q1 (Q1 is any group given for Q), alkylene-Q1, (CRaRa1)r1O(CRaRa1)r-Q1, (CRaRa1)r1NRa(CRaRa1)r-Q1, etc.; R4, R4a = H, substituted alkyl, alkenyl or alkynyl; alternatively R1 and R2, R1 and R3, R3 and R4a may form rings (with provisos)] or a stereoisomer or pharmaceutically acceptable salt were prepd. as metalloprotease and TNF-α inhibitors. Thus, N-hydroxy-1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-3-azetidinecarboxamide was prepd. by a multistep procedure involving reactions of Me 4-hydroxyphenylacetate, 2-methyl-4-quinolinylmethanol, and 3-azetidinecarboxylic acid Me ester.

IT **362701-40-4P** **362701-42-6P**
RL: BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of β-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-α)

RN 362701-40-4 HCAPLUS

CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(3-pyridinylmethyl)-, (3R)-, tris(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362701-39-1
CMF C31 H33 N5 O4

Absolute stereochemistry.

10267207
ODP = but later filing date



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 362701-42-6 HCAPLUS
CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(3-pyridinylmethyl)-, (3S)-, tris(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362701-41-5
CMF C31 H33 N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 362698-05-3P 362698-06-4P 362698-07-5P
362699-83-0P 362699-84-1P 362699-85-2P
362699-86-3P 362699-87-4P 362699-88-5P
362701-39-1P 362701-41-5P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of β-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-α)

RN 362698-05-3 HCAPLUS
CN 4-Piperidineacetamide, N-hydroxy-4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)





RN 362698-06-4 HCAPLUS
CN 4-Piperidineacetamide, N-hydroxy-4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(3-pyridinylmethyl)- (9CI) (CA INDEX

NAME)

PAGE 1-A



PAGE 2-A



RN 362698-07-5 HCAPLUS
CN 4-Piperidineacetamide, N-hydroxy-4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





RN 362699-83-0 HCAPLUS
CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 362699-84-1 HCAPLUS
CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(3-pyridinylmethyl)-, tris(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362699-83-0
CMF C31 H33 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 362699-85-2 HCAPLUS
CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



PAGE 2-A



RN 362699-86-3 HCAPLUS
CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(2-pyridinylmethyl)-, tris(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362699-85-2
CMF C31 H33 N5 O4

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 362699-87-4 HCAPLUS
CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)





RN 362699-88-5 HCAPLUS
CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(4-pyridinylmethyl)-, tris(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362699-87-4
CMF C31 H33 N5 O4

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 362701-39-1 HCAPLUS
CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(3-pyridinylmethyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 362701-41-5 HCAPLUS
CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(3-pyridinylmethyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **362704-13-0P 362704-14-1P 362704-15-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of β-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-α)
RN 362704-13-0 HCAPLUS
CN 4-Piperidineacetic acid, 4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(2-pyridinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 362704-14-1 HCAPLUS
CN 4-Piperidineacetic acid, 4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(3-pyridinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 362704-15-2 HCAPLUS
CN 4-Piperidineacetic acid, 4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(4-pyridinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L6 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2001:713343 HCAPLUS
DOCUMENT NUMBER: 135:272894
TITLE: Preparation of β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α
INVENTOR(S): Duan, Jingwu; King, Bryan W.; Decicco, Carl; **Maduskuie, Thomas P., Jr.**; Voss, Matthew E.
PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 483 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001070734	A2	20010927	WO 2001-US8336		20010315
WO 2001070734	A3	20020314			
W: AT, AU, BR, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, HU, IL, IN, JP, KR, LT, LU, LV, NZ, PL, PT, RO, SE, SG, SI, SK, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR					
CA 2400168	AA	20010927	CA 2001-2400168		20010315
AU 2001050850	A5	20011003	AU 2001-50850		20010315
EP 1263756	A2	20021211	EP 2001-924171		20010315
EP 1263756	B1	20040225			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR					
BR 2001009469	A	20030429	BR 2001-9469		20010315
JP 2003528097	T2	20030924	JP 2001-568935		20010315
AT 260272	E	20040315	AT 2001-924171		20010315
NZ 521245	A	20040430	NZ 2001-521245		20010315
ES 2215893	T3	20041016	ES 2001-1924171		20010315
US 2002013341	A1	20020131	US 2001-811116		20010316
US 6495565	B2	20021217			
HK 1049334	A1	20040716	HK 2003-101437		20030226
PRIORITY APPLN. INFO.:			US 2000-190183P	P	20000317
			US 2000-235467P	P	20000926
			US 2000-252062P	P	20001120
			WO 2001-US8336	W	20010315

NO 09811,116 NO

OTHER SOURCE(S): MARPAT 135:272894

AB Novel β-amino acid derivs. A-CR3R4aCR2R4NR1CO-X-Z-Ua-Xa-Ya-Za [A = CO2H, SH, CH2SH, S(O)Ra:NH (Ra = H, alkyl), P(O)(OH)2, etc.; X, Xa is absent or alkylene, alkenylene or alkynylene; Z is absent or substituted C3-13 carbocycle or 5-14 membered heterocycle; Ua is absent or O, NRa1 [Ra1 = H, (un)substituted alkyl, alkenyl or alkynyl; Ra and Ra1 may form a ring], CO, CO2, O2C, CONRa1, S(O)p (p = 0-2), etc.; Ya is absent or O, NRa1, S(O)p or CO; Za is H, substituted C3-13 carbocycle or 5-14 membered heterocycle; R1 is H, alkyl, Ph, benzyl; R2 is Q (Q is H, substituted carbocycle or heterocycle), alkylene-Q, (CRaRa1)r1O(CRaRa1)r-Q (r, r1 = 0-4), (CRaRa1)r1NRa(CRaRa1)r-Q, etc.; R3 = Q1 (Q1 is any group given for Q), alkylene-Q1, (CRaRa1)r1O(CRaRa1)r-Q1, (CRaRa1)r1NRa(CRaRa1)r-Q1, etc.; R4, R4a = H, substituted alkyl, alkenyl or alkynyl; alternatively R1 and R2, R1 and R3, R3 and R4a may form rings (with provisos)] or a stereoisomer or pharmaceutically acceptable salt were prepd. as metalloprotease and TNF-α inhibitors. Thus, N-hydroxy-1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-3-azetidinecarboxamide was prepd. by a multistep procedure involving reactions of Me 4-hydroxyphenylacetate, 2-methyl-4-quinolinylmethanol, and 3-azetidinecarboxylic acid Me ester.

IT **362701-40-4P** **362701-42-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of β-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-α)

RN 362701-40-4 HCAPLUS

CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(3-pyridinylmethyl)-, (3R)-, tris(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362701-39-1
CMF C31 H33 N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 362701-42-6 HCAPLUS
CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(3-pyridinylmethyl)-, (3S)-, tris(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362701-41-5
CMF C31 H33 N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **362698-05-3P 362698-06-4P 362698-07-5P**
362699-83-0P 362699-84-1P 362699-85-2P
362699-86-3P 362699-87-4P 362699-88-5P
362701-39-1P 362701-41-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of β-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-α)

RN 362698-05-3 HCAPLUS
CN 4-Piperidineacetamide, N-hydroxy-4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)





RN 362698-06-4 HCAPLUS
CN 4-Piperidineacetamide, N-hydroxy-4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



PAGE 2-A



RN 362698-07-5 HCAPLUS
CN 4-Piperidineacetamide, N-hydroxy-4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 362699-83-0 HCAPLUS
CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 362699-84-1 HCAPLUS
CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(3-pyridinylmethyl)-, tris(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362699-83-0
CMF C31 H33 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 362699-85-2 HCAPLUS

CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 362699-86-3 HCAPLUS

CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(2-pyridinylmethyl)-, tris(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362699-85-2
CMF C31 H33 N5 O4





CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 362699-87-4 HCAPLUS
CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)





RN 362699-88-5 HCAPLUS

CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(4-pyridinylmethyl)-, tris(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362699-87-4

CMF C31 H33 N5 O4





CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 362701-39-1 HCAPLUS
CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(3-pyridinylmethyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 362701-41-5 HCAPLUS
CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(3-pyridinylmethyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **362704-13-0P** **362704-14-1P** **362704-15-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of β-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-α)

RN 362704-13-0 HCAPLUS
CN 4-Piperidineacetic acid, 4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(2-pyridinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)





RN 362704-14-1 HCAPLUS

CN 4-Piperidineacetic acid, 4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(3-pyridinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)





RN 362704-15-2 HCAPLUS

CN 4-Piperidineacetic acid, 4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(4-pyridinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)





L6 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | More Like This | References

ACCESSION NUMBER: 2001:713294 HCAPLUS
DOCUMENT NUMBER: 135:257169
TITLE: Preparation of cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α
INVENTOR(S): Duan, Jingwu; Ott, Gregory; Chen, Linhua; Lu, Zhonghui; **Maduskuie, Thomas P., Jr.**; Voss, Matthew E.; Xue, Chu-Biao
PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 298 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070673	A2	20010927	WO 2001-US8334	20010315
WO 2001070673	A3	20020314		
W: AT, AU, BR, CA, CH, CN, CZ, DE, DK, EE, ES, FI, HU, IN, JP, KR, LT, LU, LV, MX, NZ, PL, PT, RO, SE, SG, SI, SK, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2401870	AA	20010927	CA 2001-2401870	20010315
EP 1263755	A2	20021211	EP 2001-924170	20010315
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
BR 2001009467	A	20030603	BR 2001-9467	20010315
JP 2003528072	T2	20030924	JP 2001-568885	20010315
EE 200200529	A	20040216	EE 2002-529	20010315
NZ 521248	A	20040430	NZ 2001-521248	20010315
US 2002016336	A1	20020207	US 2001-811233	20010316
US 6743807	B2	20040601		
US 2004162426	A1	20040819	US 2004-779539	20040213

PRIORITY APPLN. INFO.:

US 2000-190182P	P	20000317
US 2000-233373P	P	20000918
US 2000-255539P	P	20001214
WO 2001-US8334	W	20010315
US 2001-811233	A3	20010316

OTHER SOURCE(S): MARPAT 135:257169

AB Novel cyclic β-amino acid derivs. A-CRR2aCRR2bNR1CO-Z-Ua-Xa-Ya-Za [A = CO2H, CH2CO2H, SH, CH2SH, S(O)Ra:NH (Ra = H, alkyl, Ph, benzyl), P(O)(OH)2, etc.; CRCR is a substituted 3-13 membered nonarom. carbocyclic or heterocyclic ring; Z is absent or substituted C3-13 carbocycle or 5-14

membered heterocycle; Ua is absent or O, NRa1 (Ra1 = H, alkyl), CO, CO2, O2C, CONRa1, S(O)p (p = 0-2), etc.; Xa is absent or C1-10 alkylene, C2-10 alkenylene or alkynylene; Ya is absent or O, NRa1, S(O)p or CO; Za is H, substituted C3-13 carbocycle or 5-14 membered heterocycle; R1 is H, C1-4 alkyl, Ph, benzyl; R2a is H, C1-6 alkyl, ORa, NRaRa1 or S(O)pRa; R2b is H, C1-6 alkyl (with provisos)] or pharmaceutically acceptable salts were prepd. as metalloprotease and TNF-α inhibitors. Thus, (3S,4S)-N-hydroxy-1-isopropyl-4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-3-pyrrolidinecarboxamide was prepd. by a multistep procedure starting with condensation of benzyl Me maleate, glycine, and paraformaldehyde to form 3,4-pyrroledicarboxylate diester and involving amidation of 4-[(2-methyl-4-quinolinyl)methoxy]benzoic acid.

IT **362486-16-6P 362486-17-7P 362486-64-4P 362486-65-5P 362486-68-8P 362486-69-9P 362486-72-4P 362486-73-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of cyclic β-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-α)

RN 362486-16-6 HCAPLUS
CN 4-Piperidinecarboxamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(3-pyridinylcarbonyl)-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 362486-17-7 HCAPLUS
CN 4-Piperidinecarboxamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(3-pyridinylcarbonyl)-, (3S,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362486-16-6
CMF C30 H29 N5 O5

Absolute stereochemistry.





CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 362486-64-4 HCAPLUS
CN 4-Piperidinecarboxamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(4-pyridinylmethyl)-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 362486-65-5 HCAPLUS
CN 4-Piperidinecarboxamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(4-pyridinylmethyl)-, (3S,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362486-64-4
CMF C30 H31 N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 362486-68-8 HCAPLUS
CN 4-Piperidinecarboxamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(2-pyridinylmethyl)-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 362486-69-9 HCAPLUS
CN 4-Piperidinecarboxamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(2-pyridinylmethyl)-, (3S,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362486-68-8
CMF C30 H31 N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 362486-72-4 HCAPLUS
CN 4-Piperidinecarboxamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(3-pyridinylmethyl)-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 362486-73-5 HCAPLUS
CN 4-Piperidinecarboxamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(3-pyridinylmethyl)-, (3S,4S)-,

bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362486-72-4
CMF C30 H31 N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



=> d his

(FILE 'HOME' ENTERED AT 16:51:14 ON 03 MAY 2005)

FILE 'REGISTRY' ENTERED AT 16:51:22 ON 03 MAY 2005
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 29 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 16:58:17 ON 03 MAY 2005
L4 9 S L3
L5 0 S L4 AND ZHONGHUI, L?/AU
L6 3 S L4 AND MADUSKUIE, T?/AU

=> s l4 not l6
L7 6 L4 NOT L6

```
=> s l7 and voss, m?/au
           202 VOSS, M?/AU
L8           0 L7 AND VOSS, M?/AU

=> s l7 and xue, c?/au
           689 XUE, C?/AU
L9           0 L7 AND XUE, C?/AU

=> s l7 and duan, j?/au
           823 DUAN, J?/AU
L10          1 L7 AND DUAN, J?/AU

=> s l10 not l6
L11          1 L10 NOT L6

=> d l11, ibib abs hitstr, 1

L11  ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2005 ACS on STN
```

Full Text | Citing References

ACCESSION NUMBER: 2003:950052 HCAPLUS
DOCUMENT NUMBER: 140:13040
TITLE: Combined use of TACE inhibitors and COX2 inhibitors as anti-inflammatory agents
INVENTOR(S): **Duan, Jingwu**
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

10/453036 = APD = ND

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2003225054	A1	20031204	US 2003-453036		20030603
PRIORITY APPLN. INFO.:			US 2002-385656P	P	20020603

OTHER SOURCE(S): MARPAT 140:13040

AB This invention relates to a method of treating inflammatory diseases in a mammal comprising administering to the mammal a therapeutically effective amt. of a combination of: (i) at least one TACE inhibitor, (ii) one or more anti-inflammatory agents selected from the group consisting of: selective COX-2 inhibitors, interleukin-1 antagonists, dihydroorotate synthase inhibitors, p38 MAP kinase inhibitors, TNF-α inhibitors, TNF-α sequestration agents, and methotrexate. The invention also relates to compns. and kits contg. the same.

IT **362699-87-4**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combined use of TACE inhibitors and COX2 inhibitors as anti-inflammatory agents)

RN 362699-87-4 HCAPLUS
CN 3-Piperidineacetamide, N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)






```
=> d his

     (FILE 'HOME' ENTERED AT 16:51:14 ON 03 MAY 2005)

     FILE 'REGISTRY' ENTERED AT 16:51:22 ON 03 MAY 2005
L1               STRUCTURE UPLOADED
L2             0 S L1
L3            29 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 16:58:17 ON 03 MAY 2005
L4             9 S L3
L5             0 S L4 AND ZHONGHUI, L?/AU
L6             3 S L4 AND MADUSKUIE, T?/AU
L7             6 S L4 NOT L6
L8             0 S L7 AND VOSS, M?/AU
L9             0 S L7 AND XUE, C?/AU
L10            1 S L7 AND DUAN, J?/AU
L11            1 S L10 NOT L6

=> s l7 not l11
L12            5 L7 NOT L11

=> s l12 and ott, g?/au
           346 OTT, G?/AU
L13            0 L12 AND OTT, G?/AU

=> s l12 and chen, l?/au
         15829 CHEN, L?/AU
L14            0 L12 AND CHEN, L?/AU
```

```
=> s l12 and decicco, c?/au
           132 DECICCO, C?/AU
L15          0 L12 AND DECICCO, C?/AU

=> s lu, z?/au and maduskuie and maduskuie, t?/au and voss, m?/au and xuie, c?/au an
          6248 LU, Z?/AU
             0 MADUSKUIE
            34 MADUSKUIE, T?/AU
           202 VOSS, M?/AU
             0 XUIE, C?/AU
           823 DUAN, J?/AU
           346 OTT, G?/AU
         15829 CHEN, L?/AU
           132 DECICCO, C?/AU
L16          0 LU, Z?/AU AND MADUSKUIE AND MADUSKUIE, T?/AU AND VOSS, M?/AU
               AND XUIE, C?/AU AND DUAN, J?/AU AND OTT, G?/AU AND CHEN, L?/AU
               AND DECICCO, C?/AU

=> file caold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      46.71     212.98

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -2.92      -2.92

FILE 'CAOLD' ENTERED AT 17:05:10 ON 03 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file supports REGistRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
  more information.

=> d his

     (FILE 'HOME' ENTERED AT 16:51:14 ON 03 MAY 2005)

     FILE 'REGISTRY' ENTERED AT 16:51:22 ON 03 MAY 2005
L1               STRUCTURE UPLOADED
L2             0 S L1
L3            29 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 16:58:17 ON 03 MAY 2005
L4             9 S L3
```

```
L5              0 S L4 AND ZHONGHUI, L?/AU
L6              3 S L4 AND MADUSKUIE, T?/AU
L7              6 S L4 NOT L6
L8              0 S L7 AND VOSS, M?/AU
L9              0 S L7 AND XUE, C?/AU
L10             1 S L7 AND DUAN, J?/AU
L11             1 S L10 NOT L6
L12             5 S L7 NOT L11
L13             0 S L12 AND OTT, G?/AU
L14             0 S L12 AND CHEN, L?/AU
L15             0 S L12 AND DECICCO, C?/AU
L16             0 S LU, Z?/AU AND MADUSKUIE AND MADUSKUIE, T?/AU AND VOSS, M?/AU

     FILE 'CAOLD' ENTERED AT 17:05:10 ON 03 MAY 2005

=> s l3
L17           0 L3

=>
```

546 | 26 → 112 → 134 → 135

COZD

453 | 02



1-[(pyridin-3-yl)carbonyl]-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

514 | 183 → 277 → 279 → 299 → 311 → 314

N-hydroxy-3-({4-[(2-methyl-3-pyridinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide

21
C070/68

546 / 1 → 184 → 192 →
193 → 194 →

514 / 163 → 277 → 315 →

317 → 318 →

A61K 31/445



n-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-[2-(4-morpholinyl)-2-oxoethyl]-4-piperidinecarboxamide

COMP 413/00

544/1 → 63 → 98 → 106 →

111 → 124 → 125 → 127

514/183 → 277 → 279 → 299 → 311 → 314



N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-[[(2R)-2-pyrrolidinyl]methyl]-4-piperidinecarboxamide



N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-[2-(4-morpholinyl)-2-oxoethyl]-4-piperidinecarboxamide



N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(3-tetrahydropyrrolidinyl)-4-piperidinecarboxamide



1-[1-[[(1,1-dimethylethyl)oxy]carbonyl]-3-tetrahydropyrrolidinyl]-n-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide



N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-tetrahydropyranyl)-4-piperidinecarboxamide



N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-[[2-(2-thienyl)ethyl]carbamyl]-4-piperidinecarboxamide



N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-morpholinecarbonyl)-4-piperidinecarboxamide



n-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-morpholinecarbonyl)-3-piperidinecarboxamide



1-(2,2-dimethylbutanoyl)-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

COTD 215/02

= S46/1 → 26 → 112 →

152 → 165 → 166

A61C 31/47 S14/ 277 → 279 → 299 →

311 → 314



(3s,4R)-1-[(butoxy)carbonyl]-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

p. 29



(3S,4S)-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carboyl]amino]-3-piperidinecarboxamide



1-(2-thiazolylmethyl)-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]3-piperidinecarboxamide



N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-pyridinylmethyl)-4-piperidinecarboxamide